Shire PLC (SHPG) Downgraded to Hold at ValuEngine

ValuEngine cut shares of Shire PLC (NASDAQ:SHPG) from a buy rating to a hold rating in a research report sent to investors on Friday morning.

Several other equities research analysts have also recently commented on the company. Zacks Investment Research cut Shire PLC from a hold rating to a sell rating in a report on Monday, July 17th. BidaskClub cut Shire PLC from a hold rating to a sell rating in a report on Saturday, July 1st. BTIG Research reaffirmed a buy rating and issued a $242.00 price target on shares of Shire PLC in a report on Monday, July 17th. HSBC Holdings plc cut Shire PLC from a hold rating to a reduce rating in a report on Friday, May 19th. Finally, Stifel Nicolaus reaffirmed a buy rating and issued a $245.00 price target on shares of Shire PLC in a report on Wednesday, July 12th. One analyst has rated the stock with a sell rating, ten have given a hold rating and fourteen have given a buy rating to the company. The stock currently has a consensus rating of Buy and a consensus target price of $220.08.

Shares of Shire PLC (NASDAQ:SHPG) traded up 1.64% during trading on Friday, hitting $151.84. The stock had a trading volume of 1,173,432 shares. The firm’s 50-day moving average is $155.30 and its 200 day moving average is $170.18. Shire PLC has a 52-week low of $139.36 and a 52-week high of $209.22. The firm has a market cap of $45.23 billion, a price-to-earnings ratio of 67.94 and a beta of 1.62.

Shire PLC (NASDAQ:SHPG) last posted its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported $3.73 EPS for the quarter, beating the consensus estimate of $3.53 by $0.20. Shire PLC had a return on equity of 14.10% and a net margin of 4.70%. The firm had revenue of $3.75 billion during the quarter. During the same period in the prior year, the business posted $3.38 EPS. Shire PLC’s revenue for the quarter was up 54.2% compared to the same quarter last year. On average, analysts expect that Shire PLC will post $14.93 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This story was originally posted by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this story on another domain, it was stolen and republished in violation of US and international trademark and copyright law. The original version of this story can be accessed at https://sportsperspectives.com/2017/09/02/shire-plc-shpg-downgraded-to-hold-at-valuengine.html.

The company also recently declared a semiannual dividend, which will be paid on Friday, October 20th. Stockholders of record on Friday, September 8th will be given a dividend of $0.1527 per share. The ex-dividend date of this dividend is Thursday, September 7th. This represents a dividend yield of 0.21%. Shire PLC’s dividend payout ratio is currently 40.63%.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SHPG. Afam Capital Inc. raised its position in Shire PLC by 8.8% in the second quarter. Afam Capital Inc. now owns 29,879 shares of the biopharmaceutical company’s stock valued at $4,938,000 after buying an additional 2,410 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new position in Shire PLC during the second quarter valued at approximately $406,000. Verition Fund Management LLC raised its position in Shire PLC by 18.9% in the second quarter. Verition Fund Management LLC now owns 2,967 shares of the biopharmaceutical company’s stock valued at $490,000 after buying an additional 472 shares in the last quarter. Sterling Capital Management LLC purchased a new position in Shire PLC during the second quarter valued at approximately $299,000. Finally, Delphi Management Inc. MA raised its position in Shire PLC by 10.5% in the second quarter. Delphi Management Inc. MA now owns 13,350 shares of the biopharmaceutical company’s stock valued at $2,206,000 after buying an additional 1,270 shares in the last quarter. Institutional investors and hedge funds own 19.13% of the company’s stock.

Shire PLC Company Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Analyst Recommendations for Shire PLC (NASDAQ:SHPG)

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply